|
1) Tahiri F, Le Naour F, Huguet S, et al. Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology. 2008; 47: 937-48
|
|
|
|
2) Migita K, Abiru S, Maeda Y, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol. 2007; 68: 586-91
|
|
|
|
|
|
3) Kido M, Watanabe N, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology. 2008; 135: 1333-43
|
|
|
|
|
|
4) Oya Y, Watanabe N, Owada T, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum. 2008; 58: 2498-510
|
|
|
|
|
|
5) Abe M, Onji M, Kawai-Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol. 2007; 5: 255-8
|
|
|
|
|
|
6) Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res. 2001; 21: 213-9
|
|
|
|
|
7) Hennes EM, Zeniya M, Czaja AJ, et al. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48: 169-76
|
|
|
|
|
|
8) Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008; 48: 1540-8
|
|
|
|
|
|
9) Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007; 27: 507-15
|
|
|
|
|
|
10) Lüth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008; 42: 926-30
|
|
|
|
|
|
11) Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007; 102: 1005-12
|
|
|
|
|
|
12) Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008; 103: 1944-51
|
|
|
|
|
|
13) Lleo A, Selmi C, Invernizzi P, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009; 49: 871-9
|
|
|
|
|
|
14) Leung PS, Park O, Tsuneyama K, et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol. 2007; 179: 2651-7
|
|
|
|
|
|
15) Wakabayashi K, Lian ZX, Leung PS, et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology. 2008; 48: 531-40
|
|
|
|
|
|
16) Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004; 127: 485-92
|
|
|
|
|
|
17) Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009; 360: 2544-55
|
|
|
|
|
|
18) Ohishi Y, Nakamura M, Iio N, et al. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology. 2008; 48: 853-62
|
|
|
|
|
|
19) Harada K, Tsuneyama K, Sudo Y, et al. Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is Propionibacterium acnes involved in granuloma formation？ Hepatology. 2001; 33: 530-6
|
|
|
|
|
|
20) Bogdanos D, Pusl T, Rust C, et al. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol. 2008; 49: 466-73
|
|
|
|
|
|
21) D'Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology. 2009; 136: 1435-43
|
|
|
|
|
|
22) Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007; 45: 118-27
|
|
|
|
|
|
23) Shibuya A, Tanaka K, Miyakawa H, et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology. 2002; 35: 1172-8
|
|
|
|
|
|
24) Suzuki A, Lymp J, Donlinger J, et al. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007; 5: 259-64
|
|
|
|
|
|
25) Karrar A, Broomé U, Södergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology. 2007; 132: 1504-14
|
|
|
|
|
|
26) Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008; 48: 939-44
|
|
|
|
|
|
27) Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007; 102: 1042-9
|
|
|
|
|
|
28) Björnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008; 134: 975-80
|
|
|
|
|
|
29) Tanaka A, Takamori Y, Toda G, et al. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008; 28: 983-9
|
|
|
|
|
|
30) Charatcharoenwitthaya P, Angulo P, Enders FB, et al. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology. 2008; 47: 133-42
|
|
|
|
|
|
31) Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008; 48: 792-800
|
|
|
|
|
|
32) Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007; 45: 1538-46
|
|
|
|
|
|
33) Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008; 134: 706-15
|
|
|
|
|
|
34) Umemura T, Zen Y, Hamano H, et al. IgG4 associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis. Gut. 2007; 56: 1471-2
|
|
|
|
|
|
35) Umemura T, Zen Y, Hamano H, et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology. 2007; 46: 463-71
|
|
|
|
|